Eleanor Williams
Biotechnology Small Research Facility Coordinator
Ellie Williams is a structural biologist with a background in ITC, NMR and crystallography. She has been heading up the protein production facility since 2021. Ellie obtained her PhD with Prof. John Ladbury and Dr. Mark Williams at University College London, looking at the chaperone Hsp90. She then moved to the SGC Oxford in 2010 where she worked with Prof. Alex Bullock, studying the ultra-rare disease fibrodysplasia ossificans progressiva (FOP).
In 2021 she took over running of the protein production facility within the CMD. The facility offers support to academics across the university as well as external scientists and industry partners to provide a bespoke and tailored approach to providing high quality recombinant protein.
The facility is able to help researchers from construct design and cloning through expression and ultimately purification for a number of different applications. We operate E. coli, baculoviral insect cell and mammalian cell expression systems and regularly use a wide variety of purification techniques as relevant to the project.
The expertise offered within the facility enables us to approach more difficult proteins that require more attention to enable, or where specific help is needed to help progress a project forward. We also offer training and access to equipment for members of the University looking to purify protein themselves but without access to the relevant knowledge.
She is highly experienced in delivering public engagement in research, has experience teaching and lecturing, and takes a keen interest in Equality, Diversity and Inclusion issues.
Recent publications
-
Amino acid and viral binding by the high-affinity Cationic Amino acid
Transporter 1 (CAT1) from Mus musculus
Preprint
Sauer D. et al, (2024)
-
Crystallographic Fragment Screen of Coxsackievirus A16 2A Protease identifies new opportunities for the development of broad-spectrum anti-enterovirals.
Preprint
Lithgo RM. et al, (2024)
-
A selection of Golden Gate vectors to simplify recombinant protein production inEscherichia coli
Preprint
Fairhead M. et al, (2024)
-
Identification, mapping and relative quantitation of SARS-CoV-2 Spike glycopeptides by Mass-Retention Time Fingerprinting.
Journal article
Chalk R. et al, (2021), Commun Biol, 4
-
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva.
Journal article
Williams E. et al, (2021), JCI Insight, 6